Viz.ai, Alnylam to Advance Earlier Identification of Cardiac Amyloidosis

Viz.ai, Alnylam to advance earlier identification of cardiac amyloidosis

Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis.

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today at 9:30 am ET –CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),... L'articolo Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association è un contenuto originale di 01net.

Viz.ai and Alnylam Pharmaceuticals Partner to Launch AI Care Pathway for Cardiac Amyloidosis

What You Should Know: The Partnership: Viz.ai, a major player in AI-powered care coordination, has partnered with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.The Clinical Problem: Cardiac amyloidosis (specifically ATTR-CM and AL) is a progressive, often fatal condition where misfolded proteins deposit in the heart muscle. Because its symptoms mimic generalized heart failure, it is chronically underdiagnosed, causing patients to miss t…